Chimeric antigen receptors targeting B-cell maturation antigen
AssigneeThe United States of America, as represented by the Secretary, Dept. of Health and Human Services
InventorJames N. Kochenderfer
Life of this patent
Estimating the term…
Abstract
The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
Claims59
A chimeric antigen receptor (CAR) comprising an antigen recognition moiety directed against B-cell Maturation Antigen (BCMA), a transmembrane domain, and one or more intracellular T cell signaling domains.
A CAR comprising:
- a signal sequence polypeptide;
- an antibody or antigen binding fragment thereof directed against BCMA;
- a CD8α hinge domain or a CD28 hinge domain;
- a CD8α transmembrane domain or a CD28 transmembrane domain;
- a 4-1BB intracellular T cell signaling domain, an OX40 intracellular T cell signaling domain, or a CD28 intracellular T cell signaling domain;
- and a CD3ζ intracellular T cell signaling domain.
A CAR comprising:
- a CD8α signal sequence polypeptide;
- an scFv directed against BCMA;
- a CD8α hinge domain or a CD28 hinge domain;
- a CD8α transmembrane domain or a CD28 hinge domain;
- a 4-1BB intracellular T cell signaling domain, an OX40 intracellular T cell signaling domain, or a CD28 intracellular T cell signaling domain;
- and a CD3ζ intracellular T cell signaling domain.
Dependencies are inferred from the claim text.